Market Place
Sourcing Support
Altamira Therapeutics Provides Update on Nasdaq Listing
04 Oct 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Extended ISO 13485 Certification
27 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Business Update, H1 2024 Results
24 Sep 2024 //
GLOBENEWSWIRE
Altamira To Host H1 2024 Results Call
20 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Closing Of Public Offering
19 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Prices $12.0 Million Public Offering
17 Sep 2024 //
GLOBENEWSWIRE
Altamira Expands Bentrio Agreement With Nuance Pharma
16 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Altamira Extends Bentrio Distribution To Sweden And Denmark With Pharma Nordic
23 Aug 2024 //
GLOBENEWSWIRE
Altamira Confirms Suitability For Athletes With No Prohibited Substances
16 Aug 2024 //
GLOBENEWSWIRE
Altamira Reports Enhanced Immunotherapy With Zbtb46 mRNA Delivery
12 Aug 2024 //
GLOBENEWSWIRE
Altamira Publishes Data On SOD2 mRNA Treatment For Aortic Aneurysm
19 Jul 2024 //
GLOBENEWSWIRE
Altamira Highlights Review Supporting Betahistine In Vertigo Management
20 Jun 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Business Update
28 May 2024 //
GLOBENEWSWIRE
Altamira Bentrio Social Amplification: Seasonal Allergy Positive Results
23 May 2024 //
GLOBENEWSWIRE
Altamira: Patent For siRNA Nanoparticles In Cancer, Inflammation
01 May 2024 //
GLOBENEWSWIRE
Altamira`s Bentrio Allergic Rhinitis Data Published
24 Apr 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Financial Update, Reports FY 2023 Results
10 Apr 2024 //
GLOBENEWSWIRE
Altamira Therapeutics to Host Full Year 2023 Financial Results
04 Apr 2024 //
GLOBENEWSWIRE
Altamira Files Second Patent Application for OligoPhore Nanoparticles
24 Jan 2024 //
GLOBENEWSWIRE
Altamira Regains Compliance with Nasdaq Minimum Bid Price Requirement
29 Dec 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Investor and Business Update
11 Dec 2023 //
GLOBENEWSWIRE
Altamira lays off 25% of staff weeks after allergy spray spinoff
11 Dec 2023 //
FIERCE BIOTECH
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
05 Dec 2023 //
GLOBENEWSWIRE
Altamira Regains Compliance with Nasdaq Minimum Stockholders` Equity Requirement
29 Nov 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
17 Nov 2023 //
GLOBENEWSWIRE
Altamira Announces Patent Office Decision to Grant for Intranasal Betahistine
10 Nov 2023 //
GLOBENEWSWIRE
Altamira Reports Additional Significant Efficacy Outcomes from Bentrio Trial
14 Sep 2023 //
GLOBENEWSWIRE
Altamira Provides Business Update and First Half 2023 Financial Results
12 Sep 2023 //
GLOBENEWSWIRE
Altamira Therapeutics to Host First Half 2023 Financial Results
06 Sep 2023 //
GLOBENEWSWIRE
Altamira to Present at H.C. Wainwright 25th Annual Investment Conference
23 Aug 2023 //
GLOBENEWSWIRE
Altamira and Pharma Nordic Collaborate for Marketing of Bentrio in Scandinavia
20 Jul 2023 //
GLOBENEWSWIRE
Altamira Announces Publication of Positive Results from Trial with Bentrio
17 Jul 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
06 Jul 2023 //
ACCESSWIRE
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics
05 Jul 2023 //
GLOBENEWSWIRE
Altamira Announces IND Clearance by FDA for AM-125 in Acute Vestibular Syndrome
15 Jun 2023 //
ACCESSWIRE
Altamira Announces Publication of Article on Peptide-Based RNA Delivery
31 May 2023 //
ACCESSWIRE
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial
24 May 2023 //
ACCESSWIRE
Altamira Therapeutics Provides Business Update, Reports FY 2022 FYR
16 May 2023 //
ACCESSWIRE
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results
12 May 2023 //
ACCESSWIRE
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap
01 May 2023 //
ACESSWIRE
Altamira Announces Publication of Positive Results from PII Trial with AM-125
12 Apr 2023 //
ACCESSWIRE
Altamira SemaPhore Delivery Platform Shows Synergis-tic Effects of ZBTB46 mRNA
22 Mar 2023 //
GLOBENEWSWIRE
Altamira’s RNA Delivery Platform Drives Effective Treatment of Osteoarthritis
15 Mar 2023 //
ACCESSWIRE
Clinical Study Demonstrates Bentrio`s Superior Nasal Residence Time
03 Mar 2023 //
ACCESSWIRE
Altamira Files Provisional Patent Application for OligoPhore Nanoparticles
27 Feb 2023 //
GLOBENEWSWIRE
Altamira Therapeutics to Report Bentrio Clinical Data at Feb. 25 AAAAI
14 Feb 2023 //
ACCESSWIRE
Altamira to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
07 Feb 2023 //
ACCESSWIRE
Altamira stakes for-sale sign again after asset deal crumbles
28 Jan 2023 //
FIERCE BIOTECH
Altamira Therapeutics Provides Business Update
27 Jan 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
24 Jan 2023 //
GLOBENEWSWIRE
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit
10 Jan 2023 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Year-End 2022 Business Update
19 Dec 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial
02 Dec 2022 //
ACCESSWIRE
Altamira Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
30 Nov 2022 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Business Update and First Half 2022 FYR
30 Nov 2022 //
GLOBENEWSWIRE
Vivo Data Demonstrates Altamira`s SemaPhore mRNA Delivery Platform
22 Nov 2022 //
ACCESSWIRE
Altamira to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics
10 Nov 2022 //
GLOBENEWSWIRE
